Comparative Pharmacology
Head-to-head clinical analysis: CORPHED versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORPHED versus PROMETHAZINE DM.
CORPHED vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corbined (idarucizumab) is a humanized monoclonal antibody fragment that binds to dabigatran with high affinity, neutralizing its anticoagulant effect. It acts as a specific reversal agent for dabigatran.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
10-20 mg orally twice daily; maximum 60 mg/day.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal half-life 3-4 hours; prolonged in renal impairment (up to 15 hours)
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal (70-80% as unchanged drug), biliary/fecal (20-30%)
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine/Decongestant
Antihistamine / Antiemetic